Literature DB >> 7439134

Development of a new pharmacological seizure model: effects of anticonvulsants on cortical- and amygdala-kindled seizures in the rat.

P S Albright, W M Burnham.   

Abstract

The potency of eight standard anticonvulsants was tested in dose-response studies on kindled rats. Animals with either amygdala- or cortical-generalized seizures were used, and the effects of drugs were assessed on: (1) amygdala focal activity; (2) cortical focal activity; and (3) the generalized convulsion triggered from either focus. Ethosuximide, which is used against absence attacks, was not effective at subtoxic levels against any type of kindled seizure. The seven other drugs, all of which are effective against tonic-clonic seizures, were found to be: (a) most potent against generalized convulsive seizures; (b) slightly less potent against cortical focal activity; and (c) only partially effective against amygdala focal activity even at high (toxic) doses. The effect of these drugs on kindled seizures closely parallels their known clinical effects against (respectively) tonic-clonic, simple partial, and complex partial attacks. It is concluded that the kindling preparation could provide new pharmacological models for several different types of clinical seizure. Its most important use, however, is likely to be as a model for complex partial seizures, since there is at present no satisfactory pharmacological model for these common and drug-resistant attacks.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439134     DOI: 10.1111/j.1528-1157.1980.tb04321.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  19 in total

1.  Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model.

Authors:  Doodipala S Reddy; Michael A Rogawski
Journal:  Epilepsy Res       Date:  2010-02-20       Impact factor: 3.045

2.  Conventional anticonvulsant drugs in the guinea-pig kindling model of partial seizures: effects of repeated administration.

Authors:  Trevor H Gilbert; G Campbell Teskey
Journal:  Exp Brain Res       Date:  2007-01-26       Impact factor: 1.972

3.  Neurosteroid withdrawal regulates GABA-A receptor α4-subunit expression and seizure susceptibility by activation of progesterone receptor-independent early growth response factor-3 pathway.

Authors:  O Gangisetty; D S Reddy
Journal:  Neuroscience       Date:  2010-07-27       Impact factor: 3.590

4.  Antiseizure Activity of Midazolam in Mice Lacking δ-Subunit Extrasynaptic GABA(A) Receptors.

Authors:  Sandesh D Reddy; Iyan Younus; Bryan L Clossen; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2015-03-17       Impact factor: 4.030

Review 5.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Treatment Strategies for Dravet Syndrome.

Authors:  Kelly G Knupp; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

7.  Mood stabilizer psychopharmacology.

Authors:  Todd D Gould; Guang Chen; Husseini K Manji
Journal:  Clin Neurosci Res       Date:  2002-11-14

8.  Competitive NMDA receptor antagonists raise electrically kindled generalized seizure thresholds.

Authors:  M J Croucher; K L Cotterell; H F Bradford
Journal:  Neurochem Res       Date:  1992-05       Impact factor: 3.996

9.  Lack of effect of chronic carbamazepine on brain somatostatin in the rat.

Authors:  S R Weiss; T Nguyen; D R Rubinow; C J Helke; P K Narang; R M Post; D M Jacobowitz
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

10.  Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property.

Authors:  Guy A Higgins; Nathalie Breysse; Elijus Undzys; D Richard Derksen; Melanie Jeffrey; Brian W Scott; Tao Xin; Corinne Roucard; Karine Bressand; Antoine Depaulis; W M Burnham
Journal:  Psychopharmacology (Berl)       Date:  2009-10-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.